Alignment Healthcare, Inc. Q3 FY2024 earnings call

• Membership grew 58% year-over-year to 182,300 members, surpassing year-end guidance.
• Total revenue increased 52% year-over-year to $692 million.
• Adjusted gross profit was $81 million, with a consolidated MBR of 88.4%, and adjusted EBITDA for the quarter was positive $6 million.
• CMS changes create opportunities for Alignment due to its population health management capabilities.
• 98% of members are in plans rated 4-stars or above for 2025; the California HMO contract, representing ~86% of MA membership, has earned 4-star or above ratings for 8 consecutive years.
• Nevada and North Carolina HMO contracts retained 5-star ratings for 3 consecutive years.
• For 2025, the growth target is at least 20%, with expectations of margin expansion from cohort improvement, stars advantage, a 5% weighted average benchmark increase, and scaling of the clinical model.
• Confident of achieving the 2025 adjusted EBITDA consensus of approximately $40 million.

For the third quarter of 2024, Alignment Healthcare's health plan membership reached 182,300 members, representing a 58% year-over-year growth. Total revenue stood at $692 million, a 52% year-over-year increase. Adjusted gross profit was $81 million, resulting in a consolidated MBR of 88.4%. Adjusted EBITDA for the quarter was positive $6 million. The revenue contribution from various segments isn't explicitly broken down beyond the overall health plan performance, but the membership growth and revenue figures are key indicators of segment performance.

• Fourth quarter membership is expected to be between 184,000 and 186,000 members; revenue is projected to be in the range of $663 million to $678 million; adjusted gross profit is expected to be between $67 million and $82 million; adjusted EBITDA is expected to be in the range of a loss of $10 million to positive $5 million.
• Full year 2024 revenue is expected to be in the range of $2.67 billion to $2.68 billion; adjusted gross profit is expected to be between $282 million and $297 million; adjusted EBITDA is expected to be in the range of a loss of $10 million to positive $5 million.
• Year-end membership expectation has been raised by 6,000; guidance ranges for adjusted gross profit and adjusted EBITDA have been narrowed.
• Anticipate at least 20% growth in 2025 and are confident of achieving the $40 million adjusted EBITDA consensus for 2025.

• CMS policy changes that can affect reimbursement and star standards.
• Competition from other health plans struggling to adapt to CMS's higher star standards.
• Challenges in managing utilization and costs.
• Seasonality and quarter-to-quarter dynamics that impact financial comparisons.

Q: Ryan Daniels asks about innovation and improvement in provider operations and clinical initiatives.

A: John Kao talks about investing in provider operations, automating workflows, scaling clinical operations, and using data for visibility and control.

Q: Michael Ha asks about MLR, supplemental benefits, and star ratings.

A: Thomas Freeman discusses MLR driven by investments, no major uptick in supplemental benefits, and stars advantage providing revenue and earnings tailwinds.

Q: Matthew Gillmor asks about revenue sequential decline and Care Anywhere engagement.

A: Thomas Freeman explains revenue factors and Care Anywhere progress.

Q: Adam Ron asks about margin improvement, utilization, and Part D.

A: Thomas Freeman discusses margin drivers, utilization performance, and Part D experience.

Q: John Ransom asks about growth in existing vs new markets and downstream provider contracting.

A: John Kao talks about growth in existing markets and population health management as key.

Q: Whit Mayo asks about CAHPS scores and Part D deductibles.

A: John Kao discusses care coordination fixes and Thomas Freeman talks about Part D positioning.

Q: Jessica Tassan asks about capitated contracts and Part D liability.

A: Thomas Freeman answers on contract structure and Part D tailwinds.

Q: Andrew Mok and Tiffany ask about G&A savings and durability.

A: Thomas Freeman explains SG&A seasonality and durability of savings.